NeuroSense Therapeutics Ltd. (NRSN) is a clinical-stage biotechnology company developing oral combination therapies for neurodegenerative disease. Its lead asset, PrimeC — a fixed-dose combination of ciprofloxacin and celecoxib — is in late-stage development for amyotrophic lateral sclerosis (ALS), with a Phase 2b trial published in JAMA Neurology and an FDA-cleared Phase 3 program. Shares closed Wednesday at $1.34, down 11.26% from the previous close of $1.51, confirming a decisively negative session. No verified news catalyst was identified for the move.
No verified news or fundamental catalyst found for Wednesday's decline. No new press release, Form 6-K, analyst note, or regulatory disclosure preceded the drop, and the drop is best understood as a technical event in an illiquid micro-cap. The stock trades a median of roughly 10,000 to 18,000 shares a session — only a few tens of thousands of dollars of daily turnover — so modest sell orders, or the absence of bids, can move the quote by double digits. The quoted market has recently shown spreads of several tens of cents between bid and ask, a structure consistent with a thin order book rather than a repricing of fundamentals. The decline also looks like continued unwinding of the 55% rally from $1.28 on Nov. 3 to $1.98 on Nov. 10, a move that was itself unsupported by new disclosures.
The company has been working through a listing-compliance process for most of the year. It received deficiency notices in April over the $1.00 minimum bid price and the $35 million minimum market value of listed securities, and later disclosed a delisting determination dated Oct. 1. A Nasdaq Hearings Panel appeal, scheduled for Nov. 10, temporarily stayed that determination, allowing the shares and warrants to keep trading while the company said it had regained bid-price compliance. The market value shortfall, however, has not been resolved publicly, and no decision from the panel has been announced. That unresolved binary is the single largest reason the equity struggles to hold rallies.
On Nov. 2, NeuroSense said it would fold a new neurofilament light chain analysis into its New Drug Submission to Health Canada, pushing the filing target to March 2027 from December 2026; the same day, coverage was cut to Neutral. Shares fell 28% that session. The news is now more than two weeks old, but it removed the nearest-term catalyst and left the story dependent on a filing that is still four months away and a Phase 3 program whose design is still being finalized with the FDA. Meanwhile, an at-the-market sales agreement and shelf capacity remain open, keeping dilution risk live for a company with no product revenue.
The move was idiosyncratic rather than sector-driven. There was no broad biotech or small-cap risk event behind the session, and the decline diverged from the wider market. Technically, the stock failed twice near $2.00 — the Nov. 10 close of $1.98 and the Nov. 11 intraday high of $2.085 — and has since lost the $1.50 area, leaving it roughly 30% below its 20-session average near $1.89. Volume in recent sessions has been running in the low tens of thousands of shares, far below the heavy turnover seen in early November, which amplifies percentage moves without signaling conviction.
On a 0-to-100 scale where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news paired with an extreme, rare price move, the score is 12 out of 100. No verified news was found, so the catalyst component is minimal: the disclosures that matter — the filing delay and the listing appeal — were published days or weeks earlier.
The price behavior was also unremarkable by the stock's own standards. The decline of 11.26% was about 1.6 times the average absolute daily move of roughly 7% over the past 60 sessions, and 12 of those sessions produced moves as large or larger. Thin volume removes any sense of a decisive repricing. Modest news and ordinary volatility combine into a low score.
The decisive near-term variable is the Nasdaq Hearings Panel's ruling on continued listing, which could arrive at any time and carries binary consequences for liquidity and index eligibility. Operationally, investors will focus on progress toward the March 2027 Health Canada submission, the finalized design and start-up costs of the FDA-cleared Phase 3 PARAGON trial, and the company's cash runway, given the burn rate and the standing at-the-market facility. Additional NfL biomarker analyses and any partnering discussions for Canadian commercialization are secondary watch items. Risks include further share issuance, failure to satisfy listing standards, trial delays, and the possibility that a thinly traded order book produces sharp moves in either direction without corresponding news.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions, drawn from a library of hundreds of AI trading bots covering thousands of tickers. Because bots differ widely in strategy, timeframe, performance metrics, and traded symbols, the trending list highlights only those generating the most notable results right now. It is a practical starting point for traders comparing systematic approaches, and worth reviewing alongside your own research before allocating capital.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NRSN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 43 cases where NRSN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +26.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRSN advanced for three days, in 207 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRSN as a result. In 72 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRSN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NRSN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.416) is normal, around the industry mean (3.592). P/E Ratio (-0.033) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. NRSN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRSN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology